Long Focus Capital Management LLC Purchases 7,194,503 Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Long Focus Capital Management LLC boosted its holdings in Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) by 54.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 20,494,393 shares of the biotechnology company's stock after purchasing an additional 7,194,503 shares during the period. Long Focus Capital Management LLC owned about 8.01% of Adaptimmune Therapeutics worth $11,040,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in ADAP. Jane Street Group LLC boosted its holdings in shares of Adaptimmune Therapeutics by 130.4% during the third quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company's stock valued at $166,000 after acquiring an additional 98,581 shares during the period. Virtu Financial LLC lifted its holdings in shares of Adaptimmune Therapeutics by 27.5% in the third quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company's stock valued at $96,000 after buying an additional 21,769 shares during the period. Rock Springs Capital Management LP grew its stake in shares of Adaptimmune Therapeutics by 2.4% in the 4th quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company's stock worth $1,338,000 after purchasing an additional 58,000 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Adaptimmune Therapeutics by 52.5% during the 4th quarter. Renaissance Technologies LLC now owns 2,526,524 shares of the biotechnology company's stock worth $1,361,000 after acquiring an additional 869,949 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in Adaptimmune Therapeutics by 82.0% during the 4th quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company's stock worth $34,000 after buying an additional 28,526 shares during the period. Institutional investors and hedge funds own 31.37% of the company's stock.

Adaptimmune Therapeutics Price Performance

Shares of ADAP stock traded up $0.01 during trading hours on Monday, hitting $0.27. The company had a trading volume of 225,956 shares, compared to its average volume of 1,598,296. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85. The firm's fifty day moving average is $0.36 and its 200 day moving average is $0.55. Adaptimmune Therapeutics plc has a 12 month low of $0.20 and a 12 month high of $1.48. The firm has a market capitalization of $70.22 million, a price-to-earnings ratio of -1.24 and a beta of 2.84.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last posted its quarterly earnings data on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.09). Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%. The firm had revenue of $3.22 million for the quarter, compared to analyst estimates of $16.56 million. On average, sell-side analysts predict that Adaptimmune Therapeutics plc will post -0.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ADAP has been the subject of several recent analyst reports. HC Wainwright decreased their target price on Adaptimmune Therapeutics from $3.50 to $3.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Scotiabank reduced their price objective on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating for the company in a research note on Friday, March 21st. Wells Fargo & Company dropped their price target on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an "equal weight" rating on the stock in a research report on Friday, March 21st. StockNews.com began coverage on Adaptimmune Therapeutics in a research note on Tuesday, April 22nd. They set a "buy" rating for the company. Finally, Jones Trading lowered shares of Adaptimmune Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 11th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, Adaptimmune Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $1.83.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.